March 2012- Volume 8, Issue 3

March 2012

In this Issue

Research & Development

IMUC, University of Pa. in deal for dendritic-cell production technology

IMUC, University of Pa. in deal for dendritic-cell production technology

ImmunoCellular Therapeutics (IMUC) announced in late February that it has entered into an agreement with the University of Pennsylvania under which the school has granted IMUC an exclusive, worldwide license for a patent-pending technology for the production of high-activity dendritic cells

Homing in on hematology

Homing in on hematology

Celgene acquires Avila Therapeutics in definitive merger agreement

Cytomedix undergoes business regeneration

Cytomedix undergoes business regeneration

Company acquires Aldagen in stock deal valued at $40 million, becomes regenerative stem-cell therapy operation

Engendering the collaborative spirit to cure MS

Engendering the collaborative spirit to cure MS

Myelin Repair Foundation, ENDECE Neural explore small- molecule compounds’ potential to reverse symptoms of multiple sclerosis

Puff the magic drug-delivery system

Puff the magic drug-delivery system

Zogenix and Battelle to collaborate on development of DosePro subcutaneous delivery technology

Amgen takes a big BiTE

Amgen takes a big BiTE

Company signs $1.16 billion merger agreement with oncology firm Micromet

Tools & Technology

Addtech adds one

Addtech adds one

Addtech Life Science closes acquisition of BioNordika

Speaking the right language

Speaking the right language

Linguamatics, Brandwatch and University Of Sussex announce project to enhance language processing of ‘big data’

A hot microplate

A hot microplate

Scripps Research, Brooks Life Science Systems partner on microplate imaging system

Building on their relationship

Building on their relationship

Vela Laboratories and Anagnostics enter strategic partnership to offer hybcell technology to biotech and pharma customers under GMP conditions

Global News

A breath of fresh air

A breath of fresh air

Almirall, BioFocus announce respiratory alliance

Two for C

Two for C

BioLineRx in-licenses two oral hepatitis C treatments

A deal with first-in-class cancer potential

A deal with first-in-class cancer potential

Merck KGaA and Threshold announce global agreement to co-develop and commercialize Phase III hypoxia-targeted drug TH-302

The power of partnering

The power of partnering

Sistemic is latest company to sign on for TiGenix’s stem cell therapy consortium

Oceania- bound and generic-focused

Oceania- bound and generic-focused

Watson Pharmaceuticals acquires Ascent Pharmahealth from Strides Arcolab for $393 million

Omics & Systems Biology

Genentech reaches for the stars

Genentech reaches for the stars

Company gains access to Constellation Pharmaceuticals’ epigenetics expertise with $95 million deal

Doing the monogenic mambo

Doing the monogenic mambo

Shire, Sangamo to develop therapies for hemophilia, other monogenic diseases

Spanish partners to develop low-cost informatics methods for clinical genomics

Spanish partners to develop low-cost informatics methods for clinical genomics

Venture attracts $1.3 million grant for ‘new frontier’ of data interpretation for clinical and diagnostic applications

IDT on deck

IDT on deck

Integrated DNA Technologies acquires 1st BASE oligonucleotide business in Singapore

Sunshine State collaboration

Sunshine State collaboration

Sanford-Burnham, Florida Hospital and Moffitt partner to develop PMP Florida

Diagnostics

Picking up a Chip

Picking up a Chip

Signal Genetics acquires ChipDX, expands molecular diagnostics assets in oncology

Trovagene closes on CLIA

Trovagene closes on CLIA

Company completes acquisition of MultiGEN Diagnostics’ clinical laboratory assets

New companions for new tests

New companions for new tests

Siemens heralds growth in CDx market with pair of partnerships

Scary dairy

Scary dairy

GeneThera acquires Applied Genetics in effort that indirectly fights Crohn’s disease

A*STAR, GE Global Research in medical imaging deal

A*STAR, GE Global Research in medical imaging deal

GE Global Research has signed a memorandum of understanding (MOU) with Singapore’s Agency of Science, Technology and Research, also known as A*STAR.

Playing hard to get

Playing hard to get

Illumina remains defiant in the wake of Roche’s takeover bid

Special Reports

Government Watch

FDA provides guidance on biosimilars

FDA provides guidance on biosimilars

The U.S. Food and Drug Administration (FDA) has issued three draft guidance documents on biosimilar product development to assist the industry in securing approval for such products in the United States.

Privacy vs. right to know

Privacy vs. right to know

Presidential Commission on Bioethics debates genome sequencing

OK as-is?

OK as-is?

Conflict-of-interest rules for FDA not needed, says agency commissioner

SPRINTing to a cure

SPRINTing to a cure

Congressional lawmakers acknowledge need to invest in U.S. research

Feature

AACR Annual Meeting 2012: Concentrated delivery

AACR Annual Meeting 2012: Concentrated delivery

In an age when diverse oncology areas must pull together and more therapeutic options emerge, AACR packs a lot into a few days

Commentary

Guest Commentary: So you want to collaborate?

Guest Commentary: So you want to collaborate?

By combining their ingenuity in a collaboration, industry and academia, for better or worse, become partners with both shared and diverse interests. As a result, the already complex inventorship matrix is made even more challenging. By combining their ingenuity in a collaboration, industry and academia, for better or worse, become partners with both shared and diverse interests. As a result, the already complex inventorship matrix is made even more challenging.

Out of Order: Watch that last step

Out of Order: Watch that last step

Every year, the pharmaceutical and biotech industries spend billions on cutting-edge R&D, clinical trials, sales and marketing and medical education and training, to get just a handful of drugs into the medical community. And yet, every year, another drug is recalled or sees its market significantly curtailed by unfortunate events in that final step— delivery to patients.

Editor's Focus

Falling short of filling unmet medical needs

Falling short of filling unmet medical needs

Shouldn’t addressing drug shortages be a top priority for an industry that claims—on every press release that crosses my desk and in most of the stories we write—that its very reason for existence is “to address a high unmet medical need?"
Subscribe to Newsletter
Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

DDN June 2022 magazine issue front cover

Latest Issue  

• Volume 18 • Issue 6 • June 2022

June 2022

June 2022 Issue